Delisting riskPopularity #3,943
HOWL · NASDAQ · Biotechnology

Werewolf Therapeutics (HOWL)

Develops conditionally activated cytokine and T-cell-engager therapies for cancer.

$0.9742
vs last close−0.01 (−0.79%)

Something off on this page? Send us feedback.

Next report
Nov 3, 26
estimated · in 41 days
EPS estimate
−$0.22
Revenue estimate
$18.3M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Jul '26Nov '26
Reported−$0.46−$0.40−$0.40−$0.36−$0.20−$0.28$0.08Pending
Estimate−$0.43−$0.44−$0.50−$0.39−$0.34−$0.32−$0.28−$0.22
Surprise−7.0%+9.1%+20.0%+7.7%+41.2%+12.5%+128.6%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Jul '26Nov '26
Reported$21.0MPending
Estimate$301.6K$375.0K$300.0K$21.0M$18.3M
Surprise0.0%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.57
Sep 2027−$0.59
Jun 2027−$0.52
Mar 2027−$0.45
Dec 2026−$0.17
Nov 2026−$0.22
Jul 2026−$0.28$0.08+128.6%
May 2026−$0.32−$0.28+12.5%
Mar 2026−$0.34−$0.20+41.2%
Nov 2025−$0.39−$0.36+7.7%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
Jun 2021
Apr 2021
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.57$9.2M
Sep 2027−$0.59$10.6M
Jun 2027−$0.52$12.1M
Mar 2027−$0.45$13.9M
Dec 2026−$0.17$16.0M
Nov 3, 2026−$0.22$18.3M
Jul 31, 2026−$0.28$0.08+128.6%$21.0M$21.0M0.0%−29.4%
May 7, 2026−$0.32−$0.28+12.5%−4.6%
Mar 27, 2026−$0.34−$0.20+41.2%$300.0K−9.5%
Nov 4, 2025−$0.39−$0.36+7.7%−7.6%
Aug 14, 2025
May 8, 2025
Mar 11, 2025
Nov 7, 2024
Aug 8, 2024
May 3, 2024
Mar 7, 2024
Nov 14, 2023
Aug 10, 2023
May 11, 2023
Mar 23, 2023
Nov 10, 2022
Aug 11, 2022
May 10, 2022
Mar 24, 2022
Nov 10, 2021
Aug 12, 2021
Jun 10, 2021
Apr 30, 2021
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.